Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;10(5):1589-1604.
doi: 10.1002/cam4.3712. Epub 2021 Jan 15.

Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research

Arthur Felix  1 , Pablo Berlanga  1 , Maud Toulmonde  2 , Judith Landman-Parker  3 , Sarah Dumont  4 , Gilles Vassal  1 , Marie-Cécile Le Deley  5 , Nathalie Gaspar  1
Affiliations

Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research

Arthur Felix et al. Cancer Med. 2021 Mar.

Abstract

Background: Optimal Phase-II design to evaluate new therapies in refractory/relapsed Ewing sarcomas (ES) remains imperfectly defined.

Objectives: Recurrent/refractory ES phase-I/II trials analysis to improve trials design.

Methods: Comprehensive review of therapeutic trials registered on five databases (who.int/trialsearch, clinicaltrials.gov, clinicaltrialsregister.eu, e-cancer.fr, and umin.ac.jp) and/or published in PubMed/ASCO/ESMO websites, between 2005 and 2018, using the criterion: (Ewing sarcoma OR bone sarcoma OR sarcoma) AND (Phase-I or Phase-II).

Results: The 146 trials identified (77 phase-I/II, 67 phase-II, and 2 phase-II/III) tested targeted (34%), chemo- (23%), immune therapies (19%), or combined therapies (24%). Twenty-three trials were ES specific and 48 had a specific ES stratum. Usually multicentric (88%), few trials were international (30%). Inclusion criteria cover the recurrent ES age range for only 12% of trials and allowed only accrual of measurable diseases (RECIST criteria). Single-arm design was the most frequent (88%) testing mainly single drugs (61%), only 5% were randomized. Primary efficacy outcome was response rate (RR=CR+PR; Complete+Partial response) (n = 116/146; 79%), rarely progression-free or overall survival (16% PFS and 3% OS). H0 and H1 hypotheses were variable (3%-25% and 20%-50%, respectively). The 62 published trials enrolled 827 ES patients. RR was poor (10%; 15 CR=1.7%, 68 PR=8.3%). Stable disease was the best response for 186 patients (25%). Median PFS/OS was of 1.9 (range 1.3-14.7) and 7.6 months (5-30), respectively. Eleven (18%) published trials were considered positive, with median RR/PFS/OS of 15% (7%-30%), 4.5 (1.3-10), and 16.6 months (6.9-30), respectively.

Conclusion: This review supports the need to develop the international randomized phase-II trials across all age ranges with PFS as primary endpoint.

Keywords: Ewing sarcoma; new cancer therapies; phase-I/II trials; trial design.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flow‐chart diagram of Ewing sarcoma phase‐I/II trials selection according to PRISMA recommendations. WHO, World Health Organization; NCT, Clinicaltrials.gov registry; EMA, European Medicines Agency registry; INCa, French Institut National du Cancer; UMIN, Japanese national registry
FIGURE 2
FIGURE 2
Geographic and temporal distribution of the 146 phase‐II trials in recurrent or refractory Ewing sarcoma. (A) Number of trials opened according to the location. (B) Number of trials opened over time
FIGURE 3
FIGURE 3
Age eligibility criteria in the 146 selected trials including refractory or recurrent Ewing sarcoma. Each trial is represented by a horizontal bar drawn from the minimal to the maximal age of inclusion. Gray horizontal bars: osteosarcoma specific trials; blue/red horizontal bars: trials with wider eligibility criteria; vertical dark line: 18 years old; vertical green line
FIGURE 4
FIGURE 4
Therapeutic interventions tested in the 146 selected phase‐I/II trials in recurrent or refractory Ewin sarcoma. (A) Therapeutic intervention type. (B) Therapeutic intervention over time between 2005 and 2018. (C) Targeted pathways in trials for targeted therapy drugs (Orange) and immunotherapy drugs (Green). Signaling pathway: Pi3k/Akt/mTOR, Igfr/ir, Raf‐braf, Tgfβ1, Sonic hedgehog, Alk, Errb, Ntrk, and Pak4. Multisignaling pathway: any multi‐tyrosine kinase Inhibitor. Epigenetic: histone deacetylase, histone demethylase‐Inhibitor, and ezh2. DNA repair: parp inhibitors. Antiangiogenic: vegf and fgf/fgfr. Transcription: anti Ews‐fli1. Metabolism: Aldh, Ascorbate, and Statin. Cell cycle: cdk4/cdk6. Immunity/inflammation: Anti‐COX2. Other: molecular‐targeted trials and Xpo‐1. Checkpoint inhibitors: antibody against PD1, PDL1, CTLA4. Adoptive cell therapy: immunotherapy that uses the patient's own T cells after in vitro treatment. Antiangiogenic antibody targeted VEGF. Anti‐inflammatory immunotherapy: IL2 aerosol. 12 years old
FIGURE 5
FIGURE 5
Description of phase‐I/II response rate in the 62 published trials according to pharmaceutical class and single drug versus combination
See this image and copyright information in PMC

References

    1. van Maldegem AM, Bhosale A, Gelderblom HJ, Hogendoorn PC, Hassan AB. Comprehensive analysis of published phase I/II clinical trials between 1990–2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment. Clin Sarcoma Res. 2012;2(1):1990‐2010. - PMC - PubMed
    1. Gaspar N, Desandes E, Orbach D, et al. Évolution de la prise en charge des sarcomes de l’enfant et de l’adolescent. Oncologie. 2016;18(4):216‐229.
    1. Kager L, Whelan J, Dirksen U, et al. The ENCCA‐WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report. Clin Sarcoma Res. 2016;6:3. - PMC - PubMed
    1. Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, Ludwig JA. Ewing’s sarcoma: standard and experimental treatment options. Curr Treat Options Oncol. 2009;10(1–2):126‐140. - PubMed
    1. Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015;33(27):3036‐3046. - PubMed

Publication types

MeSH terms

Substances